Pylera® (bismuth, metronidazole, tetracycline) Overview
In combination with omeprazole, Pylera® is indicated for the eradication of Helicobacter pylori and prevention of relapse of peptic ulcers in patients with active or a history of H.pylori associated ulcers
Pylera®:
- Is a bismuth containing 3-in-1 combination capsule with synergistic effect1,3
- Delivers >90% H.pylori eradication rate2
- Bismuth containing quadruple therapy (e.g. Pylera) is recommended as first-line in areas of high (>15%), low, or unknown clarithromycin resistance.3
A 3-in-1 synergistic action to help maximise the eradication of H.pylori1-3
In combination with omeprazole, PYLERA® is indicated for the eradication of Helicobacter pylori and prevention of relapse of peptic ulcers in patients with active or a history of H. pylori associated ulcers1
“Antibiotic resistance is the most important factor in triple therapy failure4,5”
Bismuth containing quadruple therapy (PYLERA®) increases the susceptibility of clarithromycin and metronidazole-resistant H. pylori strains3,8
References
- Pylera SmPC. (Accessed October 2024).
- Malfertheiner P, et al. Lancet. 2011;377:905–13.
- Malfertheiner P, et al. Nat Rev Dis Prim. 2023;9:19.
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management. Last updated October 2019.
- Malfertheiner P, et al. Gut. 2022;71:1724–1762.
- Savoldi A, et al. Gastroenterol. 2018;155(5):1372–1382.
- Flynn Pharma. Data on File Ref/PYL/DOF/3154. May 2024.
- Kateralis, P, et al. J Clin Gastroenterol. 2023;57:111–126.